NCT05351697View on ClinicalTrials.gov

Phase I Clinical Study of BR105 Injection

PHASE1UnknownINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

April 30, 2022

Primary Completion Date

April 30, 2023

Study Completion Date

September 30, 2025

Conditions
Advanced Malignancies
Interventions
DRUG

BR105 injection

0.2mg/kg, 1mg/kg, 3mg/kg, 10mg/kg, 20mg/kg, 30mg/kg, 40mg/kg respectively

Trial Locations (1)

100000

Beijing Cancer Hospital, Beijing

Sponsors
All Listed Sponsors
lead

BioRay Pharmaceutical Co., Ltd.

INDUSTRY